[go: up one dir, main page]

MX2016010059A - Anticuerpos útiles en la inmunización pasiva contra la gripe y composiciones, combinaciones y métodos para utilizarlos. - Google Patents

Anticuerpos útiles en la inmunización pasiva contra la gripe y composiciones, combinaciones y métodos para utilizarlos.

Info

Publication number
MX2016010059A
MX2016010059A MX2016010059A MX2016010059A MX2016010059A MX 2016010059 A MX2016010059 A MX 2016010059A MX 2016010059 A MX2016010059 A MX 2016010059A MX 2016010059 A MX2016010059 A MX 2016010059A MX 2016010059 A MX2016010059 A MX 2016010059A
Authority
MX
Mexico
Prior art keywords
methods
compositions
combinations
passive immunization
flu
Prior art date
Application number
MX2016010059A
Other languages
English (en)
Other versions
MX394775B (es
Inventor
Estelles Angeles
M Kauvar Lawrence
Vigil Adam
Wittekind Michael
Original Assignee
Contrafect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contrafect Corp filed Critical Contrafect Corp
Publication of MX2016010059A publication Critical patent/MX2016010059A/es
Publication of MX394775B publication Critical patent/MX394775B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C07K16/108—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

Se proporcionan anticuerpos, composiciones y métodos para el tratamiento y la profilaxis del virus de la gripe. Se proporcionan anticuerpos y fragmentos de unión al antígeno que se unen cerca de la secuencia de consenso del sitio de escisión de maduración Hao de la hemaglutinina A de la gripe. Además, se proporcionan composiciones de anticuerpos, combinaciones y métodos para la inmunización pasiva y eficaz en todas las cepas A y B de la gripe.
MX2016010059A 2014-02-04 2015-02-04 Anticuerpos útiles en la inmunización pasiva contra la gripe y composiciones, combinaciones y métodos para utilizarlos. MX394775B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461935746P 2014-02-04 2014-02-04
US201462051630P 2014-09-17 2014-09-17
PCT/US2015/014521 WO2015120097A2 (en) 2014-02-04 2015-02-04 Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof

Publications (2)

Publication Number Publication Date
MX2016010059A true MX2016010059A (es) 2017-04-27
MX394775B MX394775B (es) 2025-03-24

Family

ID=52469941

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010059A MX394775B (es) 2014-02-04 2015-02-04 Anticuerpos útiles en la inmunización pasiva contra la gripe y composiciones, combinaciones y métodos para utilizarlos.

Country Status (12)

Country Link
US (2) US11246928B2 (es)
EP (1) EP3102598A2 (es)
JP (3) JP6712428B2 (es)
KR (1) KR102344390B1 (es)
CN (1) CN106795216B (es)
AU (1) AU2015214146B2 (es)
BR (1) BR112016018082A2 (es)
CA (1) CA2938726A1 (es)
IL (2) IL247075A0 (es)
MX (1) MX394775B (es)
RU (1) RU2720282C1 (es)
WO (1) WO2015120097A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6800591B2 (ja) * 2016-03-11 2020-12-16 国立大学法人 岡山大学 インフルエンザ治療剤
US10815232B2 (en) 2017-01-24 2020-10-27 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline forms of viral-protein inhibitor drug VX-787, processes for preparation thereof and use thereof
SG11202006379UA (en) * 2018-01-26 2020-07-29 Regeneron Pharma Human antibodies to influenza hemagglutinin
KR20200060969A (ko) * 2018-11-23 2020-06-02 (주)셀트리온 인플루엔자 바이러스 질환을 치료하기 위한 투여 요법
RU2714246C1 (ru) * 2018-12-28 2020-02-13 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации Моноклональные антитела, специфичные к различным штаммам вируса гриппа в
PH12022550963A1 (en) * 2019-10-28 2023-09-25 Regeneron Pharma Anti-hemagglutinin antibodies and methods of use thereof
AU2021210987A1 (en) * 2020-01-24 2022-08-04 Regeneron Pharmaceuticals, Inc. Protein-antiviral compound conjugates
CN115068453A (zh) * 2021-03-15 2022-09-20 中国医学科学院药物研究所 沙美特罗防治流感的药物用途
WO2024253531A1 (en) * 2023-06-06 2024-12-12 Leyden Laboratories B.V. Bispecific antibody and use thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU745523A1 (ru) 1978-06-15 1980-07-05 Всесоюзный научно-исследовательский институт гриппа Способ профилактики и лечени острых респираторных заболеваний вирусной этиологии
US4625015A (en) 1982-08-23 1986-11-25 Scripps Clinic & Research Foundation Broad spectrum influenza antisera
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS62175426A (ja) 1986-01-27 1987-08-01 Kazufumi Shimizu 抗体及びこれを有効成分とするスプレ−剤
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US6235708B1 (en) 1998-11-20 2001-05-22 Zymogenetics, Inc Testis-specific cystatin-like protein cystatin T
US20020006656A1 (en) 1999-12-23 2002-01-17 Holloway James L. Zcys5: a member of the cystatin superfamily
WO2002081655A2 (en) 2001-03-28 2002-10-17 Children's Medical Center Corporation Fusion protein construct and method for inducing hiv-specific serum igg and secretory iga antibodies in-vivo
GB0117696D0 (en) 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
US7618629B2 (en) 2001-11-21 2009-11-17 Celltech R&D, Inc. Manipulation of cytokine levels using CD83 gene products
EP1603590A4 (en) 2003-03-07 2008-08-27 Merck & Co Inc INFLUENZA VIRUS VACCINE
CA2531684C (en) 2003-07-22 2014-03-11 Crucell Holland B.V. Binding molecules against sars-coronavirus and uses thereof
AU2004272077A1 (en) 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
US7413868B2 (en) 2003-11-05 2008-08-19 Trellis Bioscience, Inc. Use of particulate labels in bioanalyte detection methods
EP2024393A2 (en) 2006-05-15 2009-02-18 Sea Lane Biotechnologies,llc. Neutralizing antibodies to influenza viruses
US20070274985A1 (en) 2006-05-26 2007-11-29 Stefan Dubel Antibody
JP5382692B2 (ja) 2006-07-10 2014-01-08 学校法人藤田学園 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途
JP5161882B2 (ja) 2006-09-07 2013-03-13 クルセル ホランド ベー ヴェー インフルエンザウイルスｈ５ｎ１を中和しうるヒト結合性分子およびその使用
CN102046654A (zh) 2007-03-13 2011-05-04 胡马斯有限公司 针对甲型流感病毒h5n1株系的抗体
EP2160198A2 (en) 2007-05-31 2010-03-10 Statens Serum Institut Influenza vaccines
FR2921928B1 (fr) * 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
CA2708221C (en) 2007-12-06 2017-07-25 Wayne A. Marasco Antibodies against influenza virus and methods of use thereof
US8114968B2 (en) 2008-03-03 2012-02-14 Dyax Corp. Metalloproteinase-12 specific monoclonal antibody
AU2009228058A1 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
US9340603B2 (en) 2008-07-25 2016-05-17 Institute For Research In Biomedicine Neutralizing anti-influenza A virus antibodies and uses thereof
AR073072A1 (es) 2008-08-19 2010-10-13 Regeneron Pharma Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
US20120128684A1 (en) 2008-08-25 2012-05-24 Burnham Institute For Medical Research Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
WO2010074656A1 (en) 2008-12-24 2010-07-01 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof
JP5780762B2 (ja) 2008-12-25 2015-09-16 国立大学法人大阪大学 抗ヒトインフルエンザウイルス・ヒト型抗体
AU2010247530B2 (en) 2009-05-11 2016-10-13 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
CA2761681A1 (en) 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
AU2010254136B2 (en) 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
IT1400937B1 (it) 2010-03-16 2013-07-02 Ricchiuto Procedimento per ottenere propoli anallergica
WO2011117848A1 (en) 2010-03-26 2011-09-29 Pomona Ricerca S.R.L. Full-length immunoglobulins of the igg isotvpe capable of recognizing a heterosubtvpe neutralizing epitope on the hemagglutinin stem region and their use as anti-influenza medicament
EP2555795B1 (en) 2010-04-09 2016-07-13 Universiteit Utrecht Holding B.V. Recombinant multimeric influenza proteins
WO2011160083A1 (en) 2010-06-17 2011-12-22 Trellis Bioscience, Inc. Antibodies useful in passive influenza immuization
CN103097412B (zh) 2010-07-09 2016-08-10 克鲁塞尔荷兰公司 抗人呼吸道合胞病毒(rsv)抗体以及使用方法
US8900590B2 (en) 2010-08-12 2014-12-02 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
US20130289246A1 (en) 2010-09-30 2013-10-31 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
JP5944898B2 (ja) 2011-07-08 2016-07-05 新日鉄住金化学株式会社 光重合開始剤、感光性組成物及び硬化物
EA027054B1 (ru) * 2011-07-14 2017-06-30 Круселл Холланд Б.В. Связывающие молекулы человека, способные нейтрализовать вирусы гриппа a филогенетической группы 1 и филогенетической группы 2 и вирусы гриппа b
EP2793945B1 (en) * 2011-12-05 2018-08-15 Trellis Bioscience, LLC Antibodies useful in passive influenza immunization
JP6170507B2 (ja) * 2012-01-31 2017-07-26 国立大学法人大阪大学 Ｂ型インフルエンザウイルスに対する広範な保護を与えるヒトモノクローナル抗体及びその使用方法
WO2013132007A1 (en) * 2012-03-08 2013-09-12 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
EP3003373A4 (en) 2013-03-14 2016-10-19 Contrafect Corp COMPOSITION AND METHODS BASED ON INTRANASALLY RELEASED NEUTRALIZING ANTIBODIES FOR IMPROVED THERAPEUTIC EFFECTIVENESS
JP2025175426A (ja) 2024-05-20 2025-12-03 株式会社ルミカ 発光具および発光ユニット

Also Published As

Publication number Publication date
AU2015214146B2 (en) 2020-09-17
US20200054749A1 (en) 2020-02-20
WO2015120097A2 (en) 2015-08-13
AU2015214146A1 (en) 2016-08-25
KR102344390B1 (ko) 2021-12-28
EP3102598A2 (en) 2016-12-14
WO2015120097A3 (en) 2015-10-08
JP6712428B2 (ja) 2020-06-24
BR112016018082A2 (pt) 2018-02-20
CA2938726A1 (en) 2015-08-13
JP2022062126A (ja) 2022-04-19
CN106795216B (zh) 2021-04-20
JP2017511692A (ja) 2017-04-27
IL247075A0 (en) 2016-09-29
MX394775B (es) 2025-03-24
US20220111049A1 (en) 2022-04-14
US11246928B2 (en) 2022-02-15
JP7425431B2 (ja) 2024-01-31
JP7023466B2 (ja) 2022-02-22
JP2020096618A (ja) 2020-06-25
IL268431A (en) 2019-09-26
RU2720282C1 (ru) 2020-04-28
KR20160132020A (ko) 2016-11-16
US12491245B2 (en) 2025-12-09
CN106795216A (zh) 2017-05-31

Similar Documents

Publication Publication Date Title
MX2016010059A (es) Anticuerpos útiles en la inmunización pasiva contra la gripe y composiciones, combinaciones y métodos para utilizarlos.
CL2019002196A1 (es) Anticuerpos humanos neutralizantes que se unen a hemaglutinina de influenza a. (divisional solicitud 201701610)
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
EA201692467A1 (ru) Вакцины против вируса гриппа и их применения
MX389447B (es) Composiciones y métodos para anticuerpos dirigidos a bmp6.
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
IL249195A0 (en) Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
MX2016013218A (es) Molecula de unión al antígeno trifuncional.
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
HUE049081T2 (hu) GP120 elleni neutralizáló antitestek és alkalmazásuk
MX2017000985A (es) Anticuerpos anti-pd-1.
BR112017000664A2 (pt) anticorpo anti-pd-1 e seu uso
EA201692541A1 (ru) Вакцины против вируса гриппа и их применения
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
MX2016004067A (es) Anticuerpo anti-influenza a neutralizantes y usos de los mismos.
BR112016023494A2 (pt) método, aparelho e mídia legível por computador para gerar um conjunto de produtos ortopédicos recomendados.
MX2022006558A (es) Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
MX394778B (es) Método para la producción de circovirus porcino y vacunas pcv2.
MX2016009597A (es) Terapias para el influenzavirus a subtipo h7n9.
IL246643B (en) Compositions and kits for treating human immunodeficiency virus/accquired immunodeficiency syndrome
IL258238B (en) Hiv antibody compositions and methods of use
BR112017003979A2 (pt) método para a preparação de um antígeno vacinal, vacina susceptível de ser produzida pela implementação do método, e uso de um calixareno
MX2013002764A (es) Vacuna epitopica a partir de un epitope inmunogenico de la neuraminidasa del virus de la influenza ah1n1 y metodo para la obtencion del mismo.
TH1501006879A (th) ชุดเครื่อง และ วิธีการ สำหรับการเตรียมแบบเลือกได้ของ โพลีบิวทีนที่ทำปฏิกิริยา และ โพลีบิวทีนที่ไม่ทำปฏิกิริยา